TapewireFind a company

person · Reporting owner

JOHNSON DAVID EDWARD

Disclosed activity across 6 companies

Tapewire entity
36676
SEC CIK
0001785557

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
EXELIXIS, INC.EXEL · Entity 3386DirectorMay 27, 2026May 29, 2026
Liquidia CorpLQDA · Entity 1860Director · 10% ownerJune 16, 2026June 18, 2026
STANDARD BIOTOOLS INC.LAB · Entity 611610% ownerJune 29, 2023July 03, 2023
Verrica Pharmaceuticals Inc.VRCA · Entity 6823See RemarksDecember 26, 2025December 30, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

EXELIXIS, INC.

Report date May 27, 2026 · Filed May 29, 2026

Jointly reported with Caligan Partners LP

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.03 · Expires 2033-05-26Direct19,133 Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-27 · Grant · Acquired 19,133 · Balance 19,133

F1: Option granted to David Johnson ("Mr. Johnson") pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to Mr. Johnson's continuous service through such date.

F2: Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the "Caligan Master Fund") and managed accounts to which Caligan Partners LP ("Caligan") serves as investment manager (the "Caligan Accounts", together with the Caligan Master Fund, the "Caligan Master Fund and Accounts"), and may, after vesting, if applicable, transfer the securities directly to the Caligan Master Fund and Accounts.

Filing footnotes · ownership attribution and instrument terms

F1: Option granted to David Johnson ("Mr. Johnson") pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to Mr. Johnson's continuous service through such date.

F2: Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the "Caligan Master Fund") and managed accounts to which Caligan Partners LP ("Caligan") serves as investment manager (the "Caligan Accounts", together with the Caligan Master Fund, the "Caligan Master Fund and Accounts"), and may, after vesting, if applicable, transfer the securities directly to the Caligan Master Fund and Accounts.

Liquidia Corp

Report date June 16, 2026 · Filed June 18, 2026

Jointly reported with Caligan Partners LP

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, $0.001 par value per share ("Common Stock")SEC Table I · non-derivativeDirect5,882 Reported balance After 2026-06-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-06-16 · Grant · Acquired 5,882 · Balance 5,882

F1: Restricted stock units ("RSUs") convert into Common Stock on a one-for-one basis.

F2: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.

F3: David Johnson ("Mr. Johnson") is deemed to hold the securities reported herein for the benefit of certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan Partners LP ("Caligan") serves as investment manager, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds and Accounts.

Common StockSEC Table I · non-derivativeIndirectSee footnote8,157,347 Reported balance Holding disclosure · report date 2026-06-16 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 8,157,347

F4: Securities held by the Caligan Funds and Accounts to which Caligan serves as investment manager and related entities. Mr. Johnson (together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units ("RSUs") convert into Common Stock on a one-for-one basis.

F2: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.

F3: David Johnson ("Mr. Johnson") is deemed to hold the securities reported herein for the benefit of certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan Partners LP ("Caligan") serves as investment manager, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds and Accounts.

F4: Securities held by the Caligan Funds and Accounts to which Caligan serves as investment manager and related entities. Mr. Johnson (together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

STANDARD BIOTOOLS INC.

Report date June 29, 2023 · Filed July 03, 2023

Jointly reported with Caligan Partners LP

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, $0.001 par value per share ("Common Stock")SEC Table I · non-derivativeIndirectSee footnote8,467,920 Reported balance After 2023-06-29 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2023-06-29 · Other · Disposed 108,879 · Balance 8,467,920

F1: Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan.

F2: The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Common StockSEC Table I · non-derivativeIndirectSee footnote7,797,454 Reported balance After 2023-07-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2023-07-03 · Other · Disposed 670,466 · Balance 7,797,454

F1: Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan.

F3: This transaction represents an in-kind distribution by certain funds and accounts to which Caligan serves as the investment manager.

F2: The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan.

F2: The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

F3: This transaction represents an in-kind distribution by certain funds and accounts to which Caligan serves as the investment manager.

Verrica Pharmaceuticals Inc.

Report date December 26, 2025 · Filed December 30, 2025

Jointly reported with Caligan Partners LP

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.0001 per share ("Common Stock")SEC Table I · non-derivativeIndirectSee footnote923,910 Reported balance Holding disclosure · report date 2025-12-26 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 923,910

F1: This Form 3 is filed by Caligan Partners LP ("Caligan") and David Johnson with respect to the securities held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and managed accounts to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Pre-Funded Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectSee footnoteNot disclosed Reported balance Holding disclosure · report date 2025-12-26 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F2: The Pre-Funded Warrants will not expire until exercised in full.

F3: Pursuant to the terms of the Pre-Funded Warrants, the Series C Warrants and the Series B Warrants (collectively, the "Warrants"), the Reporting Persons cannot exercise any of the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Stock (the "9.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all of the Warrants reported herein due to the 9.99% Blocker.

F1: This Form 3 is filed by Caligan Partners LP ("Caligan") and David Johnson with respect to the securities held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and managed accounts to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Series C Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 · Expires 2030-11-25IndirectSee footnoteNot disclosed Reported balance Holding disclosure · report date 2025-12-26 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

F3: Pursuant to the terms of the Pre-Funded Warrants, the Series C Warrants and the Series B Warrants (collectively, the "Warrants"), the Reporting Persons cannot exercise any of the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Stock (the "9.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all of the Warrants reported herein due to the 9.99% Blocker.

F1: This Form 3 is filed by Caligan Partners LP ("Caligan") and David Johnson with respect to the securities held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and managed accounts to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Series B Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2029-11-22IndirectSee footnoteNot disclosed Reported balance Holding disclosure · report date 2025-12-26 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F3: Pursuant to the terms of the Pre-Funded Warrants, the Series C Warrants and the Series B Warrants (collectively, the "Warrants"), the Reporting Persons cannot exercise any of the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Stock (the "9.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all of the Warrants reported herein due to the 9.99% Blocker.

F1: This Form 3 is filed by Caligan Partners LP ("Caligan") and David Johnson with respect to the securities held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and managed accounts to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 3 is filed by Caligan Partners LP ("Caligan") and David Johnson with respect to the securities held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and managed accounts to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

F2: The Pre-Funded Warrants will not expire until exercised in full.

F3: Pursuant to the terms of the Pre-Funded Warrants, the Series C Warrants and the Series B Warrants (collectively, the "Warrants"), the Reporting Persons cannot exercise any of the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Stock (the "9.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all of the Warrants reported herein due to the 9.99% Blocker.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALIMERA SCIENCES INC

Report date September 16, 2024 · Filed September 18, 2024

Jointly reported with Caligan Partners LP

Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.01 per share ("Common Stock")SEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-09-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-09-16 · Other · Disposed 16,835,154 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024, by and among ANI Pharmaceuticals, Inc., a Delaware corporation ("ANI") and Alimera Sciences, Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement") as of the effective time of the merger (the "Effective Time"), each outstanding share of Common Stock was cancelled and ceased to exist and converted into the right to receive (i) $5.50 in cash, without interest and (ii) one contingent value right representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between ANI and a rights agent (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F2: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2030-03-24IndirectSee footnote0 Reported balance After 2024-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-09-16 · Other · Disposed 800,000 · Balance 0

F3: Immediately prior to the Effective Time, the warrants to purchase shares of Common Stock were net exercised and the resulting shares of Common Stock were converted into the right to receive the Merger Consideration pursuant to the terms of the Merger Agreement.

F2: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Notional Derivative Agreements (obligation to buy)SEC Table II · derivative / convertible security · Expires 2025-09-26IndirectSee footnote0 Reported balance After 2024-09-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-09-16 · Other · Disposed 1 · Balance 0

F4: As a result of the closing of the merger, the derivative agreements held by the Caligan Funds and Accounts settled in accordance with their terms based on the Merger Consideration.

F2: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024, by and among ANI Pharmaceuticals, Inc., a Delaware corporation ("ANI") and Alimera Sciences, Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement") as of the effective time of the merger (the "Effective Time"), each outstanding share of Common Stock was cancelled and ceased to exist and converted into the right to receive (i) $5.50 in cash, without interest and (ii) one contingent value right representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between ANI and a rights agent (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F2: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

F3: Immediately prior to the Effective Time, the warrants to purchase shares of Common Stock were net exercised and the resulting shares of Common Stock were converted into the right to receive the Merger Consideration pursuant to the terms of the Merger Agreement.

F4: As a result of the closing of the merger, the derivative agreements held by the Caligan Funds and Accounts settled in accordance with their terms based on the Merger Consideration.

AMAG PHARMACEUTICALS, INC.

Report date November 16, 2020 · Filed November 17, 2020

Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2020-11-16 transaction · row 1
1 source row

Row 1 · 2020-11-16 · Disposition to issuer · Disposed 14,676 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a.r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2020-11-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2020-11-16 · Disposition to issuer · Disposed 3,499,428 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a.r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F3: Such securities are held by an affiliated fund and managed account to which Caligan Partners LP ("Caligan") serves as investment manager. David Johnson is the Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0

F4: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-11-16 · Disposition to issuer · Disposed 9,452 · Balance 0

F4: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0

F4: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a.r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

F3: Such securities are held by an affiliated fund and managed account to which Caligan Partners LP ("Caligan") serves as investment manager. David Johnson is the Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

F4: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 02, 2022 Filed May 2, 2022 23:44 UTC STANDARD BIOTOOLS INC. LAB · Entity 6116 PurchaseCommon Stock 125,000 $2.81 $351,250.00
Disclosure

SEC source: 0000902664-22-002740 · ownership.xml · nonDerivative · entry 3

Caligan Partners LP · CIK 0001727492 · 10% owner

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,484,838

F4 · price: Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date for prices ranging from $ 2.71 to $2.89.

F5 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Read SEC document
April 29, 2022 Filed May 2, 2022 23:44 UTC STANDARD BIOTOOLS INC. LAB · Entity 6116 PurchaseCommon Stock 247,400 $2.66 $658,084.00
Disclosure

SEC source: 0000902664-22-002740 · ownership.xml · nonDerivative · entry 2

Caligan Partners LP · CIK 0001727492 · 10% owner

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,359,838

F3 · price: Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date for prices ranging from $2.57 to $2.70.

F5 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Read SEC document
April 28, 2022 Filed May 2, 2022 23:44 UTC STANDARD BIOTOOLS INC. LAB · Entity 6116 PurchaseCommon Stock, $0.001 par value per share ("Common Stock") 27,600 $2.40 $66,240.00
Disclosure

SEC source: 0000902664-22-002740 · ownership.xml · nonDerivative · entry 1

Caligan Partners LP · CIK 0001727492 · 10% owner

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,112,438

F1 · price: Price is the volume weighted average selling price of all sales by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $2.37 to $2.44.

F5 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Read SEC document
April 18, 2022 Filed Apr 18, 2022 22:29 UTC Liquidia Corp LQDA · Entity 1860 PurchaseCommon Stock, $0.001 par value per share 1,764,705 $5.10 $8,999,995.50
Disclosure

SEC source: 0000902664-22-002594 · ownership.xml · nonDerivative · entry 1

Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 10,093,123

F1 · ownership.nature: The securities reported herein are held by an affiliated fund to which Caligan Partners LP ("Caligan") serves as investment manager and a managed account to which Caligan serves as a consultant. David Johnson is the Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Read SEC document
April 12, 2022 Filed Apr 13, 2022 20:27 UTC STANDARD BIOTOOLS INC. LAB · Entity 6116 PurchaseCommon Stock 50,000 $3.60 $180,000.00
Disclosure

SEC source: 0000902664-22-002542 · ownership.xml · nonDerivative · entry 2

Caligan Partners LP · CIK 0001727492 · 10% owner

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,084,838

F1 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan Partners LP ("Caligan"). David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Read SEC document
April 11, 2022 Filed Apr 13, 2022 20:27 UTC STANDARD BIOTOOLS INC. LAB · Entity 6116 PurchaseCommon Stock, $0.001 par value per share ("Common Stock") 145,000 $3.87 $561,150.00
Disclosure

SEC source: 0000902664-22-002542 · ownership.xml · nonDerivative · entry 1

Caligan Partners LP · CIK 0001727492 · 10% owner

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,034,838

F1 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan Partners LP ("Caligan"). David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Read SEC document
April 08, 2022 Filed Apr 8, 2022 21:19 UTC STANDARD BIOTOOLS INC. LAB · Entity 6116 PurchaseCommon Stock 200,000 $3.76 $752,000.00
Disclosure

SEC source: 0000902664-22-002486 · ownership.xml · nonDerivative · entry 3

Caligan Partners LP · CIK 0001727492 · 10% owner

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 8,889,838

F1 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan Partners LP ("Caligan"). David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Read SEC document
April 07, 2022 Filed Apr 8, 2022 21:19 UTC STANDARD BIOTOOLS INC. LAB · Entity 6116 PurchaseCommon Stock 200,000 $3.88 $776,000.00
Disclosure

SEC source: 0000902664-22-002486 · ownership.xml · nonDerivative · entry 2

Caligan Partners LP · CIK 0001727492 · 10% owner

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 8,689,838

F1 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan Partners LP ("Caligan"). David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Read SEC document
April 06, 2022 Filed Apr 8, 2022 21:19 UTC STANDARD BIOTOOLS INC. LAB · Entity 6116 PurchaseCommon Stock, $0.001 par value per share ("Common Stock") 109,573 $3.60 $394,462.80
Disclosure

SEC source: 0000902664-22-002486 · ownership.xml · nonDerivative · entry 1

Caligan Partners LP · CIK 0001727492 · 10% owner

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 8,489,838

F1 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan Partners LP ("Caligan"). David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Read SEC document
August 20, 2021 Filed Sep 1, 2021 21:27 UTC Liquidia Corp LQDA · Entity 1860 GrantNon-Qualified Stock Option (right to buy) · Derivative 20,000 $0.00 Strike: $2.59 $0.00
Disclosure

SEC source: 0001104659-21-112115 · tm2126786-4_4seq1.xml · derivative · entry 1

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-08-20

F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024.

Read SEC document
April 13, 2021 Filed Apr 15, 2021 12:03 UTC Liquidia Corp LQDA · Entity 1860 GrantStock Option (Right to Buy) · Derivative 16,132 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0000902664-21-002335 · ownership.xml · derivative · entry 2

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,132

Underlying: Common Stock · 16,132 shares

Expires 2031-04-13

F2 · derivative.exercise_date: The stock option vests in quarterly installments, with 4,840 shares of Common Stock vesting on June 30, 2021 and 5,646 shares of Common Stock vesting on each of September 30, 2021 and December 31, 2021.

Read SEC document
April 13, 2021 Filed Apr 15, 2021 12:03 UTC Liquidia Corp LQDA · Entity 1860 GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0000902664-21-002335 · ownership.xml · derivative · entry 1

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-04-13

F1 · derivative.exercise_date: The stock option vests in 36 equal monthly installments, becoming fully vested on April 13, 2024.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:47 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 21,289 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126330 · a4.xml · derivative · entry 5

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,289 shares

Expires not disclosed

F4 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:47 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 9,452 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126330 · a4.xml · derivative · entry 4

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,452 shares

Expires not disclosed

F4 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:47 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 6,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126330 · a4.xml · derivative · entry 3

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires not disclosed

F4 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:47 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerCommon Stock 3,499,428 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126330 · a4.xml · nonDerivative · entry 2

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a.r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a.r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F3 · ownership.nature: Such securities are held by an affiliated fund and managed account to which Caligan Partners LP ("Caligan") serves as investment manager. David Johnson is the Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:47 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerCommon Stock 14,676 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126330 · a4.xml · nonDerivative · entry 1

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a.r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a.r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 17:25 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 GrantStock Option (Right to Buy) · Derivative 21,289 Not disclosed Strike: $8.52 Not disclosed
Disclosure

SEC source: 0000902664-20-002288 · ownership.xml · derivative · entry 3

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,289

Underlying: Common Stock · 21,289 shares

Expires 2030-06-02

F2 · price: Not applicable.

F4 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments commencing July 1, 2020.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 17:25 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 GrantCommon Stock, par value $0.01 per share ("Common Stock") 10,269 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-20-002288 · ownership.xml · nonDerivative · entry 1

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,676

F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments beginning on July 1, 2020; however, delivery of the shares is deferred until the earlier of (a) a Change in Control (as defined in the Issuer's Non-Employee Directors' Deferred Compensation Program) of the Issuer and (b) the date of the director's separation from service to the Issuer.

F2 · price: Not applicable.

Read SEC document
October 08, 2019 Filed Oct 10, 2019 18:11 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 GrantStock Option (Right to Buy) · Derivative 9,452 Not disclosed Strike: $11.58 Not disclosed
Disclosure

SEC source: 0000902664-19-003962 · ownership.xml · derivative · entry 4

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,452

Underlying: Common Stock · 9,452 shares

Expires 2029-10-08

F2 · price: Not applicable.

F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in seven equal monthly installments commencing November 1, 2019.

Read SEC document
October 08, 2019 Filed Oct 10, 2019 18:11 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 GrantStock Option (Right to Buy) · Derivative 6,000 Not disclosed Strike: $11.58 Not disclosed
Disclosure

SEC source: 0000902664-19-003962 · ownership.xml · derivative · entry 3

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2029-10-08

F2 · price: Not applicable.

F4 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twenty-four equal monthly installments over two years from the date of grant.

Read SEC document
October 08, 2019 Filed Oct 10, 2019 18:11 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 GrantCommon Stock, par value $0.01 per share ("Common Stock") 4,407 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-19-003962 · ownership.xml · nonDerivative · entry 1

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,407

F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in seven equal monthly installments beginning on November 1, 2019; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer.

F2 · price: Not applicable.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.